StreetAlpha.app
Home › Stocks › MESO

Mesoblast Ltd (MESO)

Healthcare
$11.91
▼ −4.34%
LAST CLOSE · NOV 17

Mesoblast develops cell therapies for inflammatory diseases, led by Ryoncil, approved in the US for a transplant complication in children. It last closed at $11.91 on Nov 17, down 4.34% on the day. MESO last reported earnings on Thu, Feb 26, 2026.

AI Auto Pilots
Is MESO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$65.4M
+1053.2% vs a year ago
Net income
−$94.4M
−144.3% margin
Free cash flow
−$60.6M
−92.7% margin
Balance sheet
Cash & equivalents
$130.0M
At Dec 31
Debt
$126.9M
At Dec 31
Shareholder equity
$574.7M
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2021: $7.4M$7.4MFY2021FY2022: $10.2M$10.2MFY2022FY2023: $7.5M$7.5MFY2023FY2024: $5.9M$5.9MFY2024FY2025: $17.2M$17.2MFY2025

From MESO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Aug 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Feb 26
2026 · Before the open (BMO)
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
±10.7%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated MESO in the past 90 days, not enough for a consensus
Average 12-month target
$39.00
▲ 227.5% upside

Based on 1 analyst who set a price target on MESO in the past 90 days. The average target is $39.00, with a high of $39.00 and a low of $39.00, compared with the last close of $11.91.

$10$20$31$41PAST 11 TRADING DAYS12-MONTH TARGETSHIGH $39AVG $39LOW $39Jun 29LAST CLOSE+12 MO$10$20$31$41PAST 11 DAYSTARGETSHIGH $39AVG $39LOW $39Jun 29LAST CLOSE+12 MO
Highest target$39.00
Average target$39.00
Lowest target$39.00
Latest rating changes
Piper SandlerReiterated
Aug 27Buy$39
DateFirmActionRatingPrice target
Aug 27Piper SandlerReiteratedBuy$39
Loading…

Technical Analysis

MESO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 19% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Oct 19) at $11.89, and the nearest resistance the Pivot at $12.02.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.5%/day
Key levels
$21.5052 week high+80.5%
$15.16200 day average+27.3%
$15.06100 day average+26.4%
$14.47Swing high (Oct 12)+21.5%
$14.1350 day average+18.6%
$13.6120 day average+14.3%
$12.31Pivot R1+3.4%
$12.02Pivot+0.9%
$11.91Last close
$11.89Swing low (Oct 19)−0.2%
$11.7452 week low−1.4%
$11.63Pivot S1−2.4%
Indicators
RSI (14)35.02Weak, oversold below 30Neutral
MACD-0.35Below its signal lineBearish
Stochastic6.1Near the bottom of its rangeOversold
ADX (14)17.1No clear trend
Williams %R-95.8Oversold below −80, overbought above −20Oversold
CCI (20)-121.8Oversold below −100, overbought above 100Oversold
Rate of change−19.4%Change over 10 sessionsBearish
ATR (14)$0.65Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MESO

What happened before

See how MESO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MESO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MESO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MESO in the last 90 days.

Loading…

See today’s whale options flow across the market →

MESO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲36 buying vs 22 selling
  • ▲Shares held by funds +10.9%
  • ▲Funds holding +4
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding7571+5.6%
In funds' top 1000–
Held by funds–––
New / increased12 / 249 / 24+9.1%
Reduced / sold out14 / 819 / 7−15.4%
Put/call ratio1.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MESO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MESO is in one of them and how their past MESO trades turned out.

MESO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MESO in an article yet. Here's the latest on the wider market.

About Mesoblast

Mesoblast is a biotechnology company based in Melbourne, Australia, that develops cell therapies made from mesenchymal cells taken from healthy adult bone marrow. Its lead product, Ryoncil, is approved in the United States to treat a severe complication of bone marrow transplants in children and is sold to physicians at transplant centers. The company is also developing these cells for other inflammatory conditions, including chronic low back pain and heart failure. The cells can be given without donor matching and are produced at industrial scale.

Headquarters
Melbourne, Victoria, Australia